{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T16:59:59Z","timestamp":1785085199602,"version":"3.55.0"},"reference-count":183,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Technol Cancer Res Treat"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:p>Acute myeloid leukemia (AML) is a heterogeneous group of malignant clonal disorders originating from hematopoietic stem or progenitor cells. Despite significant advances in understanding its pathogenesis and the development of novel therapeutic agents, the overall prognosis for AML patients remains poor. Immunotherapies have demonstrated remarkable success in other hematologic malignancies and are increasingly being explored in AML. However, their clinical application remains challenging, owing to multiple factors such as limited target specificity, high disease heterogeneity, and the immunosuppressive bone marrow microenvironment (BMME). In this review, we provide a comprehensive overview of recent advances in four major immunotherapeutic strategies for AML: adoptive cell therapy, bispecific antibodies, immune checkpoint modulation, and cytokine-based therapies. We further discuss the key biological and clinical challenges that limit their efficacy, including antigen selection, tumor heterogeneity, and microenvironmental immune suppression, along with emerging strategies to overcome these obstacles. With continued progress in both basic and clinical research, immunotherapy holds great potential to achieve greater specificity, improved safety, and more durable responses, ultimately improving outcomes for patients with AML.<\/jats:p>","DOI":"10.1177\/15330338261473431","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T15:25:21Z","timestamp":1784906721000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Leveraging Immunotherapy in Acute Myeloid Leukemia Treatment: Opportunities and Challenges"],"prefix":"10.1177","volume":"25","author":[{"given":"Wanbin","family":"Fu","sequence":"first","affiliation":[{"name":"Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Du","sequence":"additional","affiliation":[{"name":"Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3685-5664","authenticated-orcid":false,"given":"Hua","family":"Zhong","sequence":"additional","affiliation":[{"name":"Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00108-3"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27625"},{"key":"e_1_3_4_4_2","unstructured":"SEER. Acute Myeloid Leukemia - Cancer Stat Facts."},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024027217"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27434"},{"issue":"1","key":"e_1_3_4_7_2","first-page":"46","article-title":"Acute myeloid leukemia management and research in 2025","volume":"75","author":"Kantarjian HM","year":"2025","unstructured":"Kantarjian HM, DiNardo CD, Kadia TM, et al. Acute myeloid leukemia management and research in 2025. CA Cancer J Clin. 2025;75(1):46-67.","journal-title":"CA Cancer J Clin"},{"key":"e_1_3_4_8_2","article-title":"Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study","author":"Arellano ML","year":"2025","unstructured":"Arellano ML, Thirman MJ, DiPersio JF, et al. Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study. Blood. 2025.","journal-title":"Blood"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00826"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2021.1825678"},{"key":"e_1_3_4_11_2","unstructured":"Jing LM Xue S Wang Y et al. Comparing the E. Blood. 2023;22:11."},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2025.101286"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-265603"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02685-5"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.12.013"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01217"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716863"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-696054"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.085209"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0797-730"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2019.01.031"},{"issue":"1","key":"e_1_3_4_22_2","first-page":"27","article-title":"An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia","volume":"4","author":"Lasry A","year":"2023","unstructured":"Lasry A, Nadorp B, Fornerod M, et al. An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia. Nat Cancer. 2023;4(1):27-42.","journal-title":"Nat Cancer"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.18521"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15932"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.07.016"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.70051"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.2.720"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2009.02.009"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt0102-70"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-1759(00)00343-4"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2009.210"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aay8248"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.03.005"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000937"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.03.052"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025031053"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-1643"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-025-01764-5"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.147"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.115806"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-206227"},{"key":"e_1_3_4_42_2","first-page":"11","article-title":"Development of CAR T cells Targeting a Surface RNA Binding Protein for the Treatment of Acute Leukemias","volume":"3","author":"Fujino T","year":"2026","unstructured":"Fujino T, Lewis J, Chen B, et al. Development of CAR T cells Targeting a Surface RNA Binding Protein for the Treatment of Acute Leukemias. Cancer Discov. 2026;3:11.","journal-title":"Cancer Discov"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02767-4"},{"issue":"4","key":"e_1_3_4_44_2","first-page":"103471","article-title":"Point of care CD19 chimeric antigen receptor (CAR) T-cells for relapsed\/refractory acute myeloid leukemia (AML) with aberrant CD19 antigen expression","volume":"72","author":"Danylesko I","year":"2024","unstructured":"Danylesko I, Shem-Tov N, Yerushalmi R, et al. Point of care CD19 chimeric antigen receptor (CAR) T-cells for relapsed\/refractory acute myeloid leukemia (AML) with aberrant CD19 antigen expression. Curr Res Transl Med. 2024;72(4):103471.","journal-title":"Curr Res Transl Med"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-025-01708-z"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a036251"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0009-0"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.06.022"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10102441"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-026-01466-2"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024861"},{"key":"e_1_3_4_52_2","first-page":"4","article-title":"CD180 identifies chemoresistant stem-like blasts and reveals a KMT2A-driven vulnerability in acute myeloid leukaemia","volume":"20","author":"Eltoukhy MM","year":"2026","unstructured":"Eltoukhy MM, Winton A, Masci FF, et al. CD180 identifies chemoresistant stem-like blasts and reveals a KMT2A-driven vulnerability in acute myeloid leukaemia. BioRxiv. 2026;20:4.","journal-title":"BioRxiv"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.2014.909413"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2014.164"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01232-2"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-207659"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-12-474056"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-529537"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.62"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12282"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-170201"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009759"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-208795"},{"key":"e_1_3_4_64_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01308-1"},{"key":"e_1_3_4_65_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05705-7"},{"key":"e_1_3_4_66_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-025-03998-1"},{"key":"e_1_3_4_67_2","doi-asserted-by":"publisher","DOI":"10.1634\/stemcells.2005-0519"},{"key":"e_1_3_4_68_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.70094"},{"key":"e_1_3_4_69_2","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9111238"},{"key":"e_1_3_4_70_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199809057588"},{"key":"e_1_3_4_71_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(199808)58:4<278::AID-AJH5>3.0.CO;2-N"},{"key":"e_1_3_4_72_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2313812"},{"key":"e_1_3_4_73_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024027442"},{"issue":"10","key":"e_1_3_4_74_2","first-page":"2064","article-title":"Role of NKG2D and its ligands in cancer immunotherapy","volume":"9","author":"Liu H","year":"2019","unstructured":"Liu H, Wang S, Xin J, Wang J, Yao C, Zhang Z. Role of NKG2D and its ligands in cancer immunotherapy. Am J Cancer Res. 2019;9(10):2064-2078.","journal-title":"Am J Cancer Res"},{"key":"e_1_3_4_75_2","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0307"},{"key":"e_1_3_4_76_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.186742"},{"key":"e_1_3_4_77_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.225557"},{"key":"e_1_3_4_78_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1617589"},{"key":"e_1_3_4_79_2","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000406"},{"key":"e_1_3_4_80_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-205683"},{"key":"e_1_3_4_81_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16020334"},{"key":"e_1_3_4_82_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adi1145"},{"key":"e_1_3_4_83_2","doi-asserted-by":"publisher","DOI":"10.21037\/atm-21-4255"},{"key":"e_1_3_4_84_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2020.03.019"},{"key":"e_1_3_4_85_2","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00656-2"},{"key":"e_1_3_4_86_2","first-page":"45","article-title":"Development of CAR T Cells Targeting U5 snRNP200 for the Treatment of Acute Myeloid and B-Lymphoid Leukemias","volume":"18","author":"Takeshi FJ","year":"2024","unstructured":"Takeshi FJ, Chen BY, Sievers Q, et al. Development of CAR T Cells Targeting U5 snRNP200 for the Treatment of Acute Myeloid and B-Lymphoid Leukemias. ASH. 2024;18:45.","journal-title":"ASH"},{"key":"e_1_3_4_87_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.732135"},{"key":"e_1_3_4_88_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.108587"},{"key":"e_1_3_4_89_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1198687"},{"key":"e_1_3_4_90_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910607"},{"key":"e_1_3_4_91_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102975"},{"key":"e_1_3_4_92_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-026-02648-z"},{"key":"e_1_3_4_93_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bict.2025.100030"},{"key":"e_1_3_4_94_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-024-00592-6"},{"key":"e_1_3_4_95_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01376-3"},{"key":"e_1_3_4_96_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-1639"},{"key":"e_1_3_4_97_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05768-6"},{"key":"e_1_3_4_98_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001742"},{"key":"e_1_3_4_99_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.115122"},{"key":"e_1_3_4_100_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bneo.2024.100032"},{"key":"e_1_3_4_101_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.271908"},{"key":"e_1_3_4_102_2","doi-asserted-by":"publisher","DOI":"10.1038\/icb.2014.93"},{"key":"e_1_3_4_103_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-018-0472-8"},{"key":"e_1_3_4_104_2","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2025.2608209"},{"key":"e_1_3_4_105_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010956"},{"key":"e_1_3_4_106_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP-25-00652"},{"key":"e_1_3_4_107_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2024.2346755"},{"key":"e_1_3_4_108_2","first-page":"37","article-title":"GRP78 Is Expressed on the Cell Surface of Pediatric AML Blasts and Can be Targeted with GRP78-CAR T Cells without Toxicity to Hematopoietic Progenitor Cells","volume":"13","author":"Nikhil Hebbar P","year":"2020","unstructured":"Nikhil Hebbar P, Rebecca Epperly MD, Vaidya A, Huang S, Cheng C, Stephen Gottschalk MD, Mireya Paulina Velasquez MD. GRP78 Is Expressed on the Cell Surface of Pediatric AML Blasts and Can be Targeted with GRP78-CAR T Cells without Toxicity to Hematopoietic Progenitor Cells. Blood. 2020;13:37.","journal-title":"Blood"},{"key":"e_1_3_4_109_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-024-05410-0"},{"key":"e_1_3_4_110_2","article-title":"Preclinical Evaluation of MCLA117, a CLEC12AxCD3 Bispecific Antibody Efficiently Targeting a Novel Leukemic Stem Cell Associated Antigen in AML","author":"Pieter Fokko Van Loo P","year":"2015","unstructured":"Pieter Fokko Van Loo P, Doornbos R, PhD HD, PhD SS, PhD MD, Bakker L. Preclinical Evaluation of MCLA117, a CLEC12AxCD3 Bispecific Antibody Efficiently Targeting a Novel Leukemic Stem Cell Associated Antigen in AML. Blood. 2015.","journal-title":"Blood"},{"key":"e_1_3_4_111_2","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2019.1623200"},{"key":"e_1_3_4_112_2","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000003195"},{"key":"e_1_3_4_113_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-025-04169-y"},{"key":"e_1_3_4_114_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-022-00263-4"},{"key":"e_1_3_4_115_2","article-title":"Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed\/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (\u226565 Years) AML Patients","author":"Ivana Gojo M","year":"2019","unstructured":"Ivana Gojo M, Robert K, Stuart MD, Jonathan Webster MD, Blackford A, et al. Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed\/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (\u226565 Years) AML Patients. Blood. 2019.","journal-title":"Blood"},{"key":"e_1_3_4_116_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27161"},{"key":"e_1_3_4_117_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024027506"},{"key":"e_1_3_4_118_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025029850"},{"key":"e_1_3_4_119_2","doi-asserted-by":"publisher","DOI":"10.1006\/cyto.2000.0666"},{"key":"e_1_3_4_120_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.03.018"},{"key":"e_1_3_4_121_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2020.01.001"},{"key":"e_1_3_4_122_2","doi-asserted-by":"publisher","DOI":"10.2165\/11599820-000000000-00000"},{"key":"e_1_3_4_123_2","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a016295"},{"key":"e_1_3_4_124_2","doi-asserted-by":"publisher","DOI":"10.21037\/atm-20-3191"},{"key":"e_1_3_4_125_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2022.113112"},{"key":"e_1_3_4_126_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aax5104"},{"key":"e_1_3_4_127_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2020.106442"},{"key":"e_1_3_4_128_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025032033"},{"key":"e_1_3_4_129_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.656908"},{"key":"e_1_3_4_130_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1730"},{"key":"e_1_3_4_131_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.70019"},{"key":"e_1_3_4_132_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000845"},{"key":"e_1_3_4_133_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1493329"},{"key":"e_1_3_4_134_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-025-00726-4"},{"key":"e_1_3_4_135_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1301689"},{"key":"e_1_3_4_136_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2864-x"},{"key":"e_1_3_4_137_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI129204"},{"key":"e_1_3_4_138_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature13038"},{"key":"e_1_3_4_139_2","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2022.2083957"},{"key":"e_1_3_4_140_2","first-page":"511758","article-title":"Exploring the Bone Marrow Microenvironment as a Therapeutic Barrier and Targetable Source of Crosstalk in Acute Myeloid Leukemia","volume":"16","author":"Kolosova A","year":"2026","unstructured":"Kolosova A, Mould IA, Pepper C, et al. Exploring the Bone Marrow Microenvironment as a Therapeutic Barrier and Targetable Source of Crosstalk in Acute Myeloid Leukemia. Blood Lymphat Cancer. 2026;16:511758.","journal-title":"Blood Lymphat Cancer"},{"key":"e_1_3_4_141_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-10-4169"},{"key":"e_1_3_4_142_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1000996"},{"key":"e_1_3_4_143_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-275446"},{"key":"e_1_3_4_144_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1822997"},{"key":"e_1_3_4_145_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1627161"},{"key":"e_1_3_4_146_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.05.045"},{"key":"e_1_3_4_147_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00267"},{"key":"e_1_3_4_148_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2014.12.005"},{"key":"e_1_3_4_149_2","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2021.2016005"},{"key":"e_1_3_4_150_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-10-881722"},{"key":"e_1_3_4_151_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-023-02060-8"},{"key":"e_1_3_4_152_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2025.03.041"},{"key":"e_1_3_4_153_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01572-7"},{"key":"e_1_3_4_154_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1739"},{"key":"e_1_3_4_155_2","first-page":"16","article-title":"The Dual PI3K\u03b4\u03b3 Inhibitor Duvelisib Potently Inhibits IL-6 Production and Cytokine Release Syndrome (CRS) While Maintaining CAR-T Function in Vitro and In Vivo","volume":"18","author":"Parmeshwar N","year":"2020","unstructured":"Parmeshwar N, Amatya P, Carter AJ, Ritchey JK, Niswonger J, Cooper ML, Jonathan A, DiPersio JF. The Dual PI3K\u03b4\u03b3 Inhibitor Duvelisib Potently Inhibits IL-6 Production and Cytokine Release Syndrome (CRS) While Maintaining CAR-T Function in Vitro and In Vivo. Blood. 2020;18:16.","journal-title":"Blood"},{"key":"e_1_3_4_156_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau5907"},{"key":"e_1_3_4_157_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.04.001"},{"key":"e_1_3_4_158_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007494"},{"key":"e_1_3_4_159_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26115319"},{"key":"e_1_3_4_160_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-024-00705-7"},{"key":"e_1_3_4_161_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-07151-5"},{"key":"e_1_3_4_162_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1491341"},{"key":"e_1_3_4_163_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024015200"},{"key":"e_1_3_4_164_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0564-6"},{"key":"e_1_3_4_165_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1085978"},{"key":"e_1_3_4_166_2","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2025.04.02"},{"key":"e_1_3_4_167_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2025.11.005"},{"key":"e_1_3_4_168_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003894"},{"key":"e_1_3_4_169_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-024-01207-0"},{"key":"e_1_3_4_170_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-025-01737-8"},{"key":"e_1_3_4_171_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-025-01291-5"},{"key":"e_1_3_4_172_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01541-9"},{"key":"e_1_3_4_173_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1672524"},{"key":"e_1_3_4_174_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1303935"},{"key":"e_1_3_4_175_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.605766"},{"key":"e_1_3_4_176_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2026.1608433"},{"key":"e_1_3_4_177_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-3280"},{"key":"e_1_3_4_178_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-5066"},{"key":"e_1_3_4_179_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-025-02629-5"},{"key":"e_1_3_4_180_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-026-10235-x"},{"key":"e_1_3_4_181_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2025.06.004"},{"key":"e_1_3_4_182_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.10.038"},{"key":"e_1_3_4_183_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000843420.50062.9b"},{"key":"e_1_3_4_184_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-25-0349"}],"container-title":["Technology in Cancer Research &amp; Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15330338261473431","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/15330338261473431","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15330338261473431","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T16:20:17Z","timestamp":1785082817000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/15330338261473431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":183,"alternative-id":["10.1177\/15330338261473431"],"URL":"https:\/\/doi.org\/10.1177\/15330338261473431","relation":{"has-review":[{"id-type":"doi","id":"10.1177\/15330338261473431\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338261473431\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338261473431\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338261473431\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338261473431\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338261473431\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338261473431\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338261473431\/v1\/review3","asserted-by":"object"}]},"ISSN":["1533-0346","1533-0338"],"issn-type":[{"value":"1533-0346","type":"print"},{"value":"1533-0338","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"article-number":"15330338261473431"}}